Pre-made Tarcolimab benchmark antibody ( Whole mAb, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-700
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tarcolimab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Tarcolimab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | Tarcolimab |
| Target | VEGFA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | 1cz8:HL:YX |
| 99% SI Structure | None |
| 95-98% SI Structure | 1bj1:HL:KJ;6bft:HL:AB |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Development Tech | TBC |
| Previous Name | NA |
| Gm Offical Target Name | VEGFA |
| Package |
Previous slide
Next slide
